On Tuesday, Celldex Therapeutics Inc (NASDAQ: CLDX) was 0.16% up from the session before settling in for the closing price of $25.39. A 52-week range for CLDX has been $25.08 – $53.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 30.09% over the past five years. When this article was written, the company’s average yearly earnings per share was at 16.53%. With a float of $64.10 million, this company’s outstanding shares have now reached $66.29 million.
Let’s look at the performance matrix of the company that is accounted for 160 employees. In terms of profitability, gross margin is 62.68%, operating margin of -1966.89%, and the pretax margin is -1809.4%.
Celldex Therapeutics Inc (CLDX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Celldex Therapeutics Inc stocks. The insider ownership of Celldex Therapeutics Inc is 3.31%, while institutional ownership is 103.84%. The most recent insider transaction that took place on Jun 14 ’24, was worth 608,315. In this transaction SVP AND CFO of this company sold 17,172 shares at a rate of $35.42, taking the stock ownership to the 28,125 shares. Before that another transaction happened on Jun 14 ’24, when Company’s SR. VP & CPDO sold 30,000 for $34.87, making the entire transaction worth $1,045,962. This insider now owns 9,074 shares in total.
Celldex Therapeutics Inc (CLDX) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.81 earnings per share (EPS) during the time that was less than consensus figure (set at -0.68) by -0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.53% per share during the next fiscal year.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
You can see what Celldex Therapeutics Inc (CLDX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 29.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 203.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.74, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -3.00 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Celldex Therapeutics Inc (NASDAQ: CLDX) saw its 5-day average volume 1.17 million, a positive change from its year-to-date volume of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 12.24%. Additionally, its Average True Range was 1.57.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 4.43%, which indicates a significant decrease from 18.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.12% in the past 14 days, which was lower than the 57.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.32, while its 200-day Moving Average is $37.52. Nevertheless, the first resistance level for the watch stands at $25.95 in the near term. At $26.48, the stock is likely to face the second major resistance level. The third major resistance level sits at $27.24. If the price goes on to break the first support level at $24.67, it is likely to go to the next support level at $23.91. The third support level lies at $23.38 if the price breaches the second support level.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
There are 66,288K outstanding shares of the company, which has a market capitalization of 1.69 billion. As of now, sales total 6,880 K while income totals -141,430 K. Its latest quarter income was 2,500 K while its last quarter net income were -35,840 K.
